fatty diacid chain comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-03-07. Numbers and descriptions here follow the published literature rather than marketing material.
Reverse-phase high-performance liquid chromatography with ultraviolet detection near 214 or 280 nanometres is widely used to assess purity and to resolve related impurities. Liquid chromatography coupled to mass spectrometry confirms identity through the protonated molecular ion and fragment ions formed in tandem experiments. Capillary electrophoresis and peptide mapping after enzymatic digestion supply complementary information on charge variants and modification sites. Circular dichroism and nuclear magnetic resonance can report on secondary structure in solution. Absolute quantification usually depends on an external standard, and reported purity depends on the detection wavelength and integration parameters chosen.
Lyophilised material appears as a white to off-white cake or powder that is hygroscopic, and containers are usually equilibrated to room temperature before opening to limit condensation. Dissolution is performed in water, phosphate-buffered saline, or a mildly alkaline buffer, since solubility rises above neutral pH. Gentle inversion or low-speed mixing is preferred, because vigorous vortexing can promote surface denaturation and aggregation. Complete dissolution may require several minutes, and brief sonication is sometimes applied. Passing the solution through a 0.22 micrometre membrane removes particulates but does not by itself sterilise the liquid.
Storage at minus 20 degrees Celsius or lower in a desiccated container preserves the peptide for extended periods, while working solutions are commonly held at two to eight degrees Celsius for short intervals. Light exposure and repeated freeze-thaw cycles accelerate degradation, so dividing material into single-use aliquots is generally recommended. Adsorption to glass and plastic surfaces can lower the measured concentration of dilute solutions, particularly below one milligram per millilitre. The degradation routes most often reported for GLP-1 analogues are deamidation, methionine oxidation, and backbone hydrolysis. Relative rates under specific conditions are frequently described only for individual formulations.
The company that developed the compound filed it as a long-acting analogue, and it gained first approval in 2017 for type 2 diabetes. Later authorisations from several regulators extended the indication to chronic weight management, and the World Health Organization added the glucagon-like peptide-1 receptor agonist drug class to its model list of essential medicines in 2023. Production uses solid-phase peptide synthesis followed by side-chain conjugation and chromatographic purification. Supply constraints and cost differences across regions are well documented. Literature on long-term outcomes continues to grow, with many trials reporting surrogate endpoints rather than hard clinical endpoints.
Semaglutide is a synthetic peptide of thirty-one amino acids that shares roughly ninety-four percent sequence identity with human glucagon-like peptide-1. Two substitutions resist enzymatic cleavage by dipeptidyl peptidase-4, and a fatty diacid side chain attached through a linker promotes binding to serum albumin. That albumin binding slows renal clearance and extends the circulating half-life from minutes to approximately one week. The structural changes are well established in the published literature. Whether the same modifications affect receptor signalling bias in ways that matter clinically remains an open question.
Pharmacological activity arises from agonism at the glucagon-like peptide-1 receptor, a G protein-coupled receptor expressed in the pancreas, the gastrointestinal tract, and the brainstem. Receptor activation raises intracellular cyclic adenosine monophosphate and enhances insulin release in a glucose-dependent manner, an effect that diminishes when blood glucose concentration is low. Other effects include slowed gastric emptying and hypothalamic satiety signalling. These pathways are described well. Receptor desensitisation rates across tissues, relative to the endogenous hormone, are still under investigation, and reported findings differ between laboratories.
| Property | Value | Notes |
|---|---|---|
| Purity assessment | RP-HPLC, 214 nm | Wavelength affects relative peak areas |
| Identity confirmation | LC-MS/MS | Precursor and fragment ion masses compared |
| Common degradation | Deamidation, oxidation | Amide and methionine residues are main sites |
| Working solution storage | 2-8 °C, short term | Longer holding favours frozen aliquots |
| Adsorption risk | Higher below 1 mg/mL | Glass and plastic surfaces both affected |
Receptor activation raises intracellular cyclic AMP through Gs coupling, which promotes glucose-dependent insulin release and suppresses glucagon secretion when blood glucose is elevated. Effects outside the pancreas include slower gastric emptying and altered appetite signalling in the hypothalamus and hindbrain. The relative contribution of each tissue to overall metabolic outcomes remains an area of active investigation. Central mechanisms in particular are inferred mainly from animal models and indirect human measures rather than direct observation.
Serum protein binding dominates the pharmacokinetic profile. The attached chain associates strongly with albumin, shielding the peptide from enzymatic attack and slowing filtration by the kidney. This interaction extends the circulation half-life to roughly one week in humans, which supports weekly administration intervals. An oral version pairs the peptide with an absorption enhancer that transiently alters gastric epithelium, permitting limited uptake; bioavailability by that route is substantially lower than by injection.
Semaglutide belongs to the glucagon-like peptide-1 receptor agonist class, a group of synthetic peptides that imitate an incretin hormone released by intestinal L cells after food intake. Native GLP-1 circulates for only a few minutes because dipeptidyl peptidase-4 cleaves it rapidly. The hormone acts on pancreatic islets, the gastrointestinal tract, and several brain regions. Because the natural peptide is short-lived, development work concentrated on analogues that keep receptor activity while resisting enzymatic breakdown and renal clearance.
Semaglutide dissolves readily in water and in aqueous buffers near neutral pH. Solubility decreases near the isoelectric point, where net charge is minimal. Common laboratory solvents include phosphate-buffered saline and dilute ammonium bicarbonate. Strongly acidic or basic conditions may accelerate hydrolysis. Working concentrations are usually prepared by diluting a concentrated stock. Vial surfaces can adsorb small amounts of peptide at low concentrations, so carrier proteins or low-binding tubes are sometimes used.
Reverse-phase high-performance liquid chromatography is the standard method for purity assessment, separating the peptide from truncated or oxidized variants. Mass spectrometry confirms molecular mass and detects modifications, while ultraviolet absorbance near 280 nanometers supports concentration measurement through tryptophan and tyrosine residues. Circular dichroism can indicate secondary structure, though the peptide is largely helical in solution, and ion-exchange chromatography resolves charge variants. Purity values above 95 percent are typical for research-grade material. Stability studies track degradation over time under defined conditions.
Lyophilized semaglutide is typically stored at temperatures between minus 20 and minus 80 degrees Celsius for long-term preservation. Short-term storage at 2 to 8 degrees Celsius is common for working aliquots. Repeated freeze-thaw cycles can degrade the peptide and are usually avoided. The molecule is hygroscopic in its solid form, so containers should remain sealed with desiccant. Solutions are less stable than powders and are generally prepared fresh. Light exposure is limited because aromatic residues can undergo photo-oxidation.
The sequence incorporates alpha-aminoisobutyric acid at position 8, replacing the alanine found in the natural hormone. This substitution blocks the primary DPP-4 recognition site and contributes most of the enzymatic stability. Albumin binding further protects the peptide and reduces the frequency of administration required to maintain active plasma levels. Because the fatty acid chain increases lipophilicity, the compound is formulated as a solution rather than a simple aqueous buffer. Researchers describe the design as an incremental optimization of earlier GLP-1 analogs rather than a wholly new scaffold.
Reported molecular weight is approximately 4113.6 daltons for the free base, and the peptide is supplied as a lyophilized powder or in buffered liquid form depending on the intended use. It is freely soluble in water when formulated with appropriate excipients, though the unconjugated peptide shows limited stability at neutral pH over long periods. Analytical characterization typically relies on reversed-phase high-performance liquid chromatography and mass spectrometry. Purity specifications for research-grade material commonly exceed ninety-five percent by area. Isotopic and impurity profiles differ between suppliers.
Semaglutide is a synthetic peptide analogue of glucagon-like peptide-1, a gut hormone released by intestinal L cells after food intake. The natural hormone acts on pancreatic and central receptors but is degraded within minutes by dipeptidyl peptidase-4 and other peptidases. Semaglutide belongs to the class of long-acting GLP-1 receptor agonists, a group distinguished by structural changes that slow breakdown and extend circulation time. Its development followed earlier short-acting analogues and reflects a general strategy in peptide drug design: preserve receptor activity while blocking proteolytic clearance.
Three structural changes define the molecule. At position 8 an alpha-aminoisobutyric acid residue replaces alanine, which blocks dipeptidyl peptidase-4 cleavage. At position 34 arginine replaces lysine, and at position 26 a lysine carries a C18 fatty diacid attached through a short linker. The fatty chain binds serum albumin, and this albumin association reduces renal filtration and enzymatic attack. The unchanged backbone retains the receptor contacts that produce signalling. The free base has the formula C187H291N45O59 and a molecular weight near 4114 daltons.
Receptor activation follows the canonical Gs pathway: binding increases intracellular cyclic AMP, which promotes protein kinase A activity. In pancreatic beta cells this amplifies glucose-dependent insulin release, so secretion rises when blood glucose is high and changes little when it is low. The same signalling suppresses glucagon release from alpha cells and slows gastric emptying. Receptors in the hypothalamus and brainstem are thought to contribute to reduced appetite and lower energy intake. Which of these effects dominates clinical outcomes remains an area of active study.
Jammu and Kashmir (abbr. J&K) is a region administered by India as a union territory consisting of the southern portion of the larger Kashmir region, which has been the subject of a border dispute between India and Pakistan since 1947 and between India and China since 1959. The Line of Control separates Jammu and Kashmir from the Pakistani-administered territories of Azad Kashmir and Gilgit-Baltistan in the west and north respectively. It lies to the north of the Indian states of Himachal Pradesh and Punjab and to the west of Ladakh which is administered by India as a union territory. Insurgency in Jammu and Kashmir has persisted in protest over autonomy and rights. In 2019, the Jammu and Kashmir Reorganisation Act was passed, reconstituting the former state of Jammu and Kashmir into two union territories: Ladakh in the east and the residuary Jammu and Kashmir in the west. Srinagar and Jammu jointly serve as the capital of the region, which is divided into two divisions and 20 districts. Jammu and Kashmir holds substantial mineral deposits, including sapphire, borax, and graphite. Agriculture and services drive the economy, with major contributors being horticulture, handicrafts, and tourism. Apple cultivation is one of the largest industries, employing 3.5 million people and producing 10% of the gross state domestic product. Despite these activities, over 10% of the population lives below the national poverty line.
The motor by Kelly and co-workers is an elegant example of how chemical energy can be used to induce controlled, unidirectional rotational motion, a process which resembles the consumption of ATP in organisms in order to fuel numerous processes. However, it does suffer from a serious drawback: the sequence of events that leads to 120° rotation is not repeatable. Kelly and co-workers have therefore searched for ways to extend the system so that this sequence can be carried out repeatedly. Unfortunately, their attempts to accomplish this objective have not been successful and currently the project has been abandoned. In 2016 David Leigh's group invented the first autonomous chemically-fuelled synthetic molecular motor. Some other examples of synthetic chemically driven rotary molecular motors that all operate by sequential addition of reagents have been reported, including the use of the stereoselective ring opening of a racemic biaryl lactone by the use of chiral reagents, which results in a directed 90° rotation of one aryl with respect to the other aryl. Branchaud and co-workers have reported that this approach, followed by an additional ring closing step, can be used to accomplish a non-repeatable 180° rotation.
Raleigh operates under a council-manager government. Raleigh City Council consists of eight members; all seats, including the Mayor's, are open for election every two years. Five of the council seats are district representatives and two seats are citywide representatives elected at-large.
=== HIV transmission and treatment === In 1981, while working at UCSF in a lab that could perform the immunologic tests needed to detect immunodeficiency in AIDS patients, Ammann observed immunodeficiency disorders in children that mirrored those of gay men who had contracted the Human Immunodeficiency Virus. Ammann's investigations into the cause of the symptoms led him to identify two new means of transmission, in utero mother to infant and blood transfusions. With the medical community wanting not to believe that AIDS could affect infants, Ammann's initial publication blood transfusion infection was rejected by prominent medical journals. This discovery changed the perception of HIV/AIDS as an epidemic solely within the gay community. In 1985, Ammann left his position at UCSF in order to work with the biotechnology firm, Genentech. There he developed clinical products focused on HIV/AIDS, and although while with Genentech a successful vaccine was not developed, the discoveries made by Ammann's research team were used by other researchers in a partially successful study performed in Thailand in 2009. In 1994, Ammann was selected to become a member of the Presidential National AIDS Task Force on Drug and Vaccine Development. Three years later, in 1996, he was recognized by POZ magazine as one of the fifty most influential AIDS researchers.
=== Transgender hormone therapy === Finasteride is sometimes used as an antiandrogen in feminizing hormone therapy for transfeminine people. There are limited clinical data on finasteride for this use and some authorities explicitly recommend against its routine use. Relatedly, the medication is considered to be limitedly useful and unnecessary in transfeminine people with testosterone levels in the normal female range. However, finasteride may be helpful in those with higher testosterone levels and symptoms like scalp hair loss and excessive body hair or who seek only partial feminization. Besides transfeminine people, finasteride is helpful in transmasculine people for preventing scalp hair loss and is better-established for this purpose, though it might impede masculinization such as clitoral growth and development of facial and body hair.
Sources: en.wikipedia.org
These frugal organisms can be cultivated in bioreactors (as opposed to being grown in fields), secrete the transformed proteins into the growth medium and, thus, substantially reduce the burden of protein purification in preparing recombinant proteins for medical use. In addition, both species can be engineered to cause secretion of proteins with human patterns of glycosylation, an improvement over conventional plant gene-expression systems. Biolex Therapeutics developed a duckweed-based expression platform; it sold the business to Synthon and declared bankruptcy in 2012. Additionally, an Israeli company, Protalix, has developed a method to produce therapeutics in cultured transgenic carrot or tobacco cells. Protalix and its partner, Pfizer, received FDA approval to market its drug, taliglucerase alfa (Elelyso), as a treatment for Gaucher's disease, in 2012.
Dyson replied that "[m]y objections to the global warming propaganda are not so much over the technical facts, about which I do not know much, but it's rather against the way those people behave and the kind of intolerance to criticism that a lot of them have." Dyson stated in an interview that the argument with Hansen was exaggerated by The New York Times, stating that he and Hansen are "friends, but we don't agree on everything." Since originally taking an interest in climate studies in the 1970s, Dyson suggested that carbon dioxide levels in the atmosphere could be controlled by planting fast-growing trees. He calculated that it would take a trillion trees to remove all carbon from the atmosphere. In a 2014 interview he said, "What I'm convinced of is that we don't understand climate... It will take a lot of very hard work before that question is settled." Dyson was a member of the academic advisory council of the Global Warming Policy Foundation.
== Prevention == Attacks of DKA can be prevented in those known to have diabetes to an extent by adherence to "sick day rules"; these are clear-cut instructions to patients on how to treat themselves when unwell. Instructions include advice on how much extra insulin to take when sugar levels appear uncontrolled, an easily digestible diet rich in salt and carbohydrates, means to suppress fever and treat infection, and recommendations on when to call for medical help. People with diabetes can monitor their own ketone levels when unwell and seek help if they are elevated.
== Plot == Kaname and Misako's marriage is drifting towards separation and divorce, and Misako has taken a lover, Aso, with Kaname's approval. Their young son, Hiroshi, does not yet know anything definite about their plans. Both are procrastinating over their decision. Kaname realizes that he is fascinated by his father-in-law's obsessions with the bunraku theater and with young mistress, O-hisa. Misako's father is a traditionalist who attempts to keep the couple engaged in the arts of Japan in order to purge the negative influence from the West.
=== ColdFusion MX 6 === Prior to 2000, Edwin Smith, an Allaire architect on JRun and later the Flash Player, Tom Harwood and Clement Wong initiated a project codenamed "Neo". This project was later revealed as a ColdFusion Server re-written completely using Java. This made portability easier and provided a layer of security on the server, because it ran inside a Java Runtime Environment. In June 2002 Macromedia released the version 6.0 product under a slightly different name, ColdFusion MX, allowing the product to be associated with both the Macromedia brand and its original branding. ColdFusion MX was completely rebuilt from the ground up and was based on the Java EE platform. ColdFusion MX was also designed to integrate well with Macromedia Flash using Flash Remoting. With the release of ColdFusion MX, the CFML language API was released with an OOP interface.
Sources: en.wikipedia.org
Filtering removes particulate matter that can block columns or scatter light. A 0.22 micrometre membrane is typical, and the filter material should be checked for peptide adsorption.
Peptides can bind to glass and plastic, so a fraction of the material leaves the solution. The effect is proportionally larger in dilute samples and can bias quantitative results.
Reverse-phase high-performance liquid chromatography is the most widely reported approach. Purity figures should always be quoted together with the wavelength, gradient, and integration parameters used.
It is a glucagon-like peptide-1 receptor agonist, often grouped with the incretin mimetics. Its backbone is modified from the human hormone to resist enzymatic degradation and to bind albumin. These two features distinguish it from the native peptide.